hotspot -WSS

hotspot

author：hotspot 2025-09-27 16:48:17 - browse：3578

David Liu and Jonathan Wosen on the STAT Summit stage. — David Liu (left) with reporter Jonathan Wosen at the 2022 STAT Summit. STAT

David Liu, the Broad Institute biochemist behind two powerful forms of genome editing, is launching a company focused on delivering gene-editing machinery to precise cells and tissues in the body, STAT has learned.

The company, known as Nvelop, already raised a $100 million seed round last year, according to PitchBook. It is being run by Jeff Walsh, a former top executive at Bluebird Bio, and it recently recruited Bluebird’s head of research, Melissa Bonner, according to two people with knowledge of the situation. Bluebird had not previously disclosed Bonner’s departure.

Nvelop is the latest entry in a race among top labs and deep-pocketed investors to solve a delivery problem that has stunted efforts to turn CRISPR and other genetic tools into disease-altering medicines. The goal is to develop a cargo system precise enough to deliver CRISPR or other machinery to cells of a researchers’ choosing, particularly tissues that have been hard to reach with previous approaches, like neurons, muscle, and blood stem cells.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies
Next article： The most pressing bird flu mysteries scientists want answered

hotspot

WSS

FDA approves Moderna’s RSV vaccine, its second licensed product

Websites selling Wegovy, Zepbound ingredients targeted by FDA

Senators tussle over abortion against the backdrop of a presidential campaign

Anthony Fauci pushes back on GOP claims during Covid hearing

Anthony Fauci pushes back on GOP claims during Covid hearing

Doctors on social media are being harassed and cyberbullied

focus

hotspot

entertainment

Affirmative action in medical school literally saved lives

Artificial intelligence use in health care faces greater scrutiny in 2024

Tori Bowie and the unacceptable rates of Black maternal death

Lilly to acquire Dermira for $1.1 billion, adding eczema drug to its pipeline

Drug repurposing or repositioning? The language matters

Congress might make insulin pumps more accessible to the blind

Medicare proposal to cover medical devices draws a mixed reaction

Novartis is flashing warning signs about its newly acquired myelofibrosis drug

Moonlake's readout produced a cash windfall. Risks remain

Lilly to acquire Dermira for $1.1 billion, adding eczema drug to its pipeline

hotspot

STAT Boddities: What happens to the brain when we get scared?

Medicare Advantage's lean provider networks lead CMS complaints

Take antibiotics after sex, CDC recommends for certain risk groups

Congress considering partial increase for doctor pay in Medicare

FTC loses bid to block Novant's North Carolina hospital merger

Artificial intelligence use in health care faces greater scrutiny in 2024

entertainment

entertainment

hotspot

entertainment